Exciting news for those with food allergies, and other life-threatening allergies. We received this today from Mylan, the maker of Epi-Pen.
We’re excited to announce that Mylan Inc. has entered into a multi-year strategic alliance agreement with Walt Disney Parks and Resorts to help enhance access to EpiPen® (epinephrine) and EpiPen Jr® (epinephrine) Auto-Injectors and increase awareness of anaphylaxis, a life-threatening (severe) allergic reaction.
Each year, millions of guests visit Walt Disney Parks and Resorts in the U.S. — many of whom are living with and/or managing severe allergies — so for us, this alliance was the perfect fit.
As you know, food allergies are on the rise and continue to be a serious health issue in America. To date, 46 states have passed policies that allow/require schools to maintain undesignated epinephrine auto-injectors for those who may experience anaphylaxis. Our hope is that the positive trend we have seen in the school setting will expand to other public settings.
The corporate alliance between Mylan and Disney will:
• Provide updated maps in Disney’s domestic theme parks and cruise ships, as well as updated signage in parks, highlighting locations of EpiPen and EpiPen Jr Auto-Injectors.
• Introduce educational resources designed to increase awareness of and preparedness for severe allergic reactions. For those living with potentially life-threatening (severe) allergies, it’s critical to have an action plan in place before booking a getaway. Like life, severe allergic reactions are unpredictable:
• Anaphylaxis can progress quickly and without warning.
• Clinical guidelines state that epinephrine is the first-line treatment for anaphylaxis, making access critical.
• Families managing known severe allergies are encouraged to follow their individual anaphylaxis action plan, which includes 1) avoiding known allergens, 2) recognizing the signs and symptoms of anaphylaxis, 3) having access to two epinephrine auto-injectors at all times, such as EpiPen Auto-Injector, and 4) seeking immediate emergency medical care should anaphylaxis occur.
The product made available at the parks is not intended to replace a person’s individual emergency anaphylaxis treatment.
The press release is pasted below and available on the EpiPen Auto-Injector media room.
Mylan Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to Enhance Access to EpiPen® (epinephrine) Auto-Injectors
EpiPen® Auto-Injector Locations Designated on Updated Guide Maps and Signage
New Multi-year Alliance to Increase Anaphylaxis Awareness through Multiple Educational Initiatives
PITTSBURGH – Nov. 7, 2014 – Mylan Inc. (Nasdaq: MYL) today announced it has signed a multi-year strategic alliance agreement with Walt Disney Parks and Resorts to help increase awareness of anaphylaxis, a life-threatening (severe) allergic reaction. The agreement includes updated maps in Disney’s domestic theme parks and on its cruise ships as well as updated signage in the parks that highlight locations with EpiPen® (epinephrine) and EpiPen Jr® (epinephrine) Auto-Injectors. Over time, the companies also will introduce a variety of educational resources designed to increase awareness of and preparedness for severe allergic reactions.
EpiPen® locations will roll out at Disney parks and on cruise ships beginning in late 2014. In addition to emergency medical services (EMS), nurses trained to administer EpiPen Auto-Injectors are available during First Aid station operating hours to assist guests experiencing a severe allergic reaction. To help guests identify EpiPen locations, Disney’s guide maps will now include an EpiPen Auto-Injector symbol and new signage at First Aid stations.
“Mylan’s mission is to provide the world’s 7 billion people access to high quality medicine and set new standards in health care. In support of this mission, we are committed to enhancing access to EpiPen Auto-Injectors and to increasing awareness of anaphylaxis. Like life, severe allergic reactions are unpredictable, so people need to be prepared,” said Mylan CEO Heather Bresch. “We are very proud to be working with Disney, which already has a strong reputation for meeting the needs of people managing severe allergies, and believe we can further raise awareness of anaphylaxis through this collaboration and our joint commitment to education.”
Anaphylaxis is unpredictable, and can progress quickly and without warning. Clinical guidelines state that epinephrine is the first-line treatment when anaphylaxis occurs, making access critical. For those with a known risk, it is important to be prepared with an anaphylaxis action plan that includes 1) avoiding known allergens, 2) recognizing the signs and symptoms of anaphylaxis, 3) having immediate access to two epinephrine auto-injectors, such as EpiPen Auto-Injector, and 4) seeking immediate emergency medical care should anaphylaxis occur.
“For our guests who live with severe allergies every day, identifying EpiPen locations is an additional tool they’ll have for their anaphylaxis management plan,” said Dr. Pamela Hymel, chief medical officer for Walt Disney Parks and Resorts. “This new strategic alliance will help raise awareness of EpiPen locations so that our Guests with severe allergies may have the best possible experience at our parks and on our cruise ships.”
Families managing known severe allergies are encouraged to follow their individual anaphylaxis action plans and carry their epinephrine auto-injectors with them at all times.